Fig. 2: Suppression of MCL-1 sensitizes TNBC cells to ABT-263 | Cell Death & Disease

Fig. 2: Suppression of MCL-1 sensitizes TNBC cells to ABT-263

From: Downregulation of MCL-1 and upregulation of PUMA using mTOR inhibitors enhance antitumor efficacy of BH3 mimetics in triple-negative breast cancer

Fig. 2

a Cell viability analysis of MDA-MB-231, MDA-MB-157, and MDA-MB-468 cells treated with indicated drug combinations for 24 h using CCK-8 kit. mTOR inhibitors (BEZ235, AZD8055, and Temsirolimus) and BH3 mimetics (ABT263 and ABT199) were supplied at 1 μM. Data represent the mean ± SEM of three independent experiments. *P < 0.05, **P < 0.01 and ***P < 0.001 vs. control group; #P < 0.05 and ##P < 0.01 vs. indicated group; NS means no significance vs. indicated group. b Representative images of colony formation assays of MDA-MB-231, MDA-MB-157, and MDA-MB-468 cells treated with 1 μM BEZ235 or AZD8055 in combination with ABT263 (1 μM). c LDH release assays of MDA-MB-231, MDA-MB-157, and MDA-MB-468 cells following exposure to no drug (control), BEZ235 (1 μM), and/or ABT263 (1 μM) for 24 h. Data represent the mean ± SEM of three independent replicates. **P < 0.01 and ***P < 0.001 vs. indicated control group. d Quantity analysis of apoptotic tests in different TNBC cells treated with no drug (control), BEZ235 (1 μM), and/or ABT263 (1 μM) for 24 h. Data represent the mean ± SEM of three independent experiments. **P < 0.01 and ***P < 0.001 vs. indicated control group; #P < 0.05, ##P < 0.01 and ###P < 0.001 vs. indicated group. e Immunoblotting analysis of expressional changes of MCL-1, BCL-XL, and BCL-2 as well as cleaved-caspase 3 and cleaved-PARP following treatments with no drugs (control), BEZ235 (1 μM) and/or ABT263 (1 μM) in MDA-MB-231, MDA-MB-157, and MDA-MB-468 cells.

Back to article page